Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponezumab in probable cerebral amyloid angiopathy
NL-OMON40546Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral amyloid angiopathy (CAA) comparing Ponezumab with Placebo (2 arms). Primary endpoint: Change in cerebrovascular reactivity slope on visual task-evoked BOLD fMRI. Started Oct 2014; status: active, not recruiting.
02
Drugs
ponezumab
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NL-OMON40546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40546.